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doi:10.1016/j.jtcvs.2006.09.054bjective: We examined the outcome of lung transplantation with the use of donors
ged 60 years or more.
ethods: From May 1994 to May 2005, 467 lung transplants were performed at our
nstitution. A total of 60 recipients received lungs from donors aged 60 years or
ore (range 60–77 years, median 65 years), whereas 407 recipients received lungs
rom younger donors (range 9–59, median 39 years).
esults: A total of 48 patients (10%) died within 30 days of surgery: 10 (17%) in
he older donor group versus 38 (9%) in the younger donor group (P  .08). The
perative mortality varied with the underlying lung disease and was higher in
ecipients presenting with pulmonary hypertension and pulmonary fibrosis than with
mphysema or cystic fibrosis. A total of 210 patients died after a median follow-up
f 25 months (range 0–136 months). The overall 5- and 10-year survivals were 57%
nd 38%, respectively. However, the 10-year survival tended to be worse in the
lder donor group (16% vs 39% in the younger donor group, P .07). Bronchiolitis
bliterans syndrome was the predominant cause of death in recipients of older
onors who survived for more than 90 days after surgery (11/17, 65% vs 45/132,
4% in recipients of younger donors surviving for90 days after surgery, P .01).
onclusions: Given the lack of organ donors, lungs from donors aged 60 years or
ore should be considered for transplantation. However, the use of donors aged
0 years or more is associated with a lower 10-year survival, and bronchiolitis
bliterans syndrome plays a significant role as the cause of late death.
ung transplantation has had increasing success and has become the mainstay
of therapy for most end-stage lung diseases. The Registry of the International
Society for Heart and Lung Transplantation reported in 2005 that more than
5,000 lung transplants have been performed worldwide, and approximately 1500
ung transplants are performed annually.1 During the past 15 years, the number of
ecipients on the waiting list has been progressively increasing and now far exceeds
he number of organs available. Consequently, the median waiting time for lung
ransplantation has nearly doubled in North America and Europe, and 20% to 30%
f the patients awaiting lung transplantation are currently dying.2
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5
TXA number of strategies have been advocated to increase
he number of donors. Some centers have developed a
iving-related lung donor program, whereas others have
ocused on non–heart beating donors to ultimately palliate
he lack of donors. Although living-related donors have
een used successfully3 and non–heart beating donors have
een shown to be feasible in humans,4 these strategies have
emained limited to a small number of patients because of
echnical, medical, and ethical considerations.
The persistent shortage of lung donors has led to increas-
ng interest in reevaluating the existing lung donor pool.
ver the years, improvement in donor management and
efinement in techniques of lung preservation have allowed
xpansion of some of the donor selection criteria without
ignificant impact on the early morbidity and mortality after
ung transplantation.5-8 However, despite the increasing use
f marginal or extended donor lungs, extension of the se-
ection criteria to donors aged 60 years or more is still
onsidered as a contraindication for lung transplantation by
he large majority of centers, and many lung donors are
urrently refused on the basis of age only. During the last
everal years, we have adopted a policy to not disqualify
onors solely on the basis of age but to consider the lungs
or transplantation if they fulfill other selection criteria. In
his report, we analyzed the results from a series of 60
onsecutive donors aged 60 years or more who were used
or lung transplantation at our institution. The early and late
utcomes were then compared with the group of recipients
ith transplants from donors aged less than 60 years at our
nstitution during the same period.
aterials and Methods
etween May 1994 and May 2005, 467 patients underwent lung
ransplantation at our institution. A total of 60 patients (12.8%)
eceived lungs from donors aged 60 years or more during this time
eriod. Data for these 60 patients were retrospectively collected
fter the study was approved by our institutional review board.
onor information included gender, smoking history, oxygen-
tion on 100% inspired fraction of oxygen, duration of intubation,
ause of death, bronchoscopy findings, chest radiography abnor-
ality, type of lung preservation, and ischemic time. The early and
ong-term outcomes for this group of patients (older donor group)
ere then compared with the group of 407 recipients who under-
ent transplantation at our institution during the same period but
eceived lungs from donors aged less than 60 years (younger donor
roup). Recipient information included age, gender, diagnosis,
ype of lung transplant, and cause of death. Cause of death was
ssigned independently at our mortality review and prospectively
ollected in the database. Follow-up was complete for all patients
Abbreviation and Acronym
BOS bronchiolitis obliterans syndromentil May 2005. i
26 The Journal of Thoracic and Cardiovascular Surgery ● FebrDonor management has been reviewed in detail elsewhere.9
riefly, all donors received intravenous methylprednisolone (15
g/kg; Solu-Medrol, Upjohn, Don Mills, Ontario, Canada) after
rain death declaration. Donors were maintained euvolemic to
void excess fluid administration, and vasopressin was often used
o maintain adequate blood pressure. The use of Euro-Collins
Fresenius, Lexington, Mass) was switched to low-potassium dex-
ran solution (Perfadex; Vitrolife, Goteborg, Sweden) for lung
reservation in April 1998. Only truly purulent secretions in distal
irways were considered as abnormal on bronchoscopy. Chest
adiography was considered abnormal in the presence of pulmo-
ary contusion or infiltrates. The last PAO2 was measured in the
perating room after donor resuscitation and management by the
etrieval team.
Surgical procedure, immunosuppression, and antibiotic pro-
hylaxis have also been reviewed in detail elsewhere.10 Recipients
ere chosen by the transplant surgeon, on the basis of blood type,
ize match, recipient status, time on the waiting list, and recipient
ge. Single lung transplant was usually performed through a pos-
erolateral thoracotomy. Bilateral lung transplant and heart–lung
ransplant were performed through a clamshell incision.
Data are expressed as means standard deviation or as median
nd range. The Student t test was used to test differences between
ontinuous variables, and the chi-square test was used for categoric
ariables. Multivariate analysis was performed by logistic regres-
ion analysis. Survival was calculated with the Kaplan–Meier
ethod, and survival curves were compared using the log–rank
est. Statview V (Abacus Concept, Berkeley, Calif) was used for
ll analyses.
esults
he number of donors aged 60 years or more, according to
he number of lung transplantations performed every year at
ur institution, is shown in Figure 1. The number of older
onors progressively increased over time, and currently
pproximate 15% to 20% of the lung transplants that are
erformed yearly at our institution.
The majority of older donors presented with no smoking
istory, no purulent secretions in distal airways, a short
igure 1. Proportion of transplants performed with donors aged
0 years or more at our institution between 1994 and 2004.
x, Transplant.ntubation time, and normal chest radiography (Table 1).
uary 2007
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TXhe cause of death was mainly intracranial bleeding and
as rarely secondary to trauma. A total of 24 donors had a
moking history. The smoking history was 20 pack-years or
ess in 10 donors and ranged between 30 and 75 pack-years
n 14 donors. Nine donors presented with a PAO2 of less than
00 mm Hg during the initial management, but only 2
onors had a PAO2 that remained less than 300 mm Hg after
ggressive donor resuscitation.
Recipient and surgical characteristics were similar be-
ween those receiving lungs from donors aged 60 years or
ore and those receiving lungs from donors aged less than
0 years (Table 2). However, more women received lungs
rom older donors, and the mean recipient age tended to be
lder in the older donor group. Forty-four of the 46 recip-
ents who underwent transplantation for pulmonary hyper-
ension (idiopathic pulmonary arterial hypertension and
isenmenger’s syndrome) received lungs from younger do-
ors. The large majority of transplants were bilateral lung
ransplant in both older and younger donors. Older donors,
owever, were not used for heart–lung transplantation. The
schemic times were similar between the younger and older
onor groups.
A total of 48 patients (10%) died within 30 days from
ransplantation: 10 (17%) in the older donor group versus 38
9%) in the younger donor group (P .08). Causes of death
able 1. Characteristics of donors aged 60 years and older
Age (years)
Median 65
Range 60-77
Gender (n)
Female 29
Male 31
Cause of death (n)
Trauma 7
Other 53
Smoking history (n)
No 34
20 pack-year 10
20 pack-year 14
Unknown 2
Duration of intubation (hours)
Median 27
Range 12-96
Bronchoscopy findings (n)
Pus in airways 2
No pus in airways 58
Chest x-ray (n)
Normal 44
Abnormal 16
Best PaO2 (mmHg)
Median 449
Range 282-592ere primary graft dysfunction in 13 patients (3 in the older P
The Journal of Thoraciconor group vs 10 in the younger donor group, P  .8),
epsis in 19 patients (5 in the older donor group vs 14 in the
ounger donor group, P  .6), and cardiac complications in
patients (2 in the older donor group vs 6 in the younger
onor group, P  .8). An additional 8 patients died of other
auses in the younger donor group.
The 30-day mortality varied with the underlying lung
isease and was significantly higher in recipients presenting
ith pulmonary fibrosis and pulmonary hypertension than
n recipients presenting with cystic fibrosis or emphysema
Table 3). In recipients presenting with cystic fibrosis, the
eath rate was 8% in the older and younger donor groups,
nd in recipients presenting with emphysema, the death rate
as 0% in the older donor group and 7% in the younger
able 2. Recipient and surgical characteristics
Older donors
(n  60)
Younger donors
(n  407) P-value
ge (years) 49  15 45  15 0.05
ender 0.07
Female 35 (58%) 187 (46%)
Male 25 (42%) 220 (54%)
iagnosis 0.6
Pulmonary fibrosis 17 (28%) 105 (26%)
Emphysema 15 (25%) 114 (28%)
Cystic fibrosis 13 (22%) 97 (24%)
Bronchiectasis 4 (7%) 11 (2%)
Pulmonary hypertension 2 (3%) 44 (11%)
Sarcoidosis 2 (3%) 9 (2%)
Re-transplant 2 (3%) 5 (1%)
Other 5 (9%) 22 (6%)
ype of transplant 0.3
Bilateral lung 55 (92%) 349 (86%)
Single lung 5 (8%) 45 (11%)
Heart-lung 0 13 (3%)
reservation solution 0.2
Perfadex 50 (83%) 312 (77%)
Euro-Collins 10 (17%) 95 (23%)
otal ischemic time (min) 0.9
First lung 247  91 258  104
Second lung 358  103 361  105
ardiopulmonary bypass 18 (30%) 167 (41%) 0.1
able 3. Postoperative (30-day) mortality according to
ecipient’s diagnosis
Older donors Younger donors P-value
ulmonary fibrosis 5/17 (29%) 13/105 (12%) 0.06
mphysema 0/15 (0%) 8/114 (7%) 0.3
ystic fibrosis 1/13 (8%) 8/97 (8%) 0.9
ulmonary hypertension 2/2 (100%) 8/44 (18%) 0.006
e-transplant 1/2 (50%) 1/5 (20%) 0.6
ulmonary hemosiderosis 1/1 (100%) /
and Cardiovascular Surgery ● Volume 133, Number 2 527
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5
TXonor group. In contrast, in the high-risk recipient group,
he age of the donor seemed to be a significant risk factor.
or pulmonary hypertension, both recipients of older donors
ied within 30 days of surgery, whereas in patients with
ulmonary fibrosis, the 30-day mortality was 29% in the
lder donor group and 12% in the younger donor group.
Multivariate logistic regression analysis demonstrated
hat a diagnosis of pulmonary fibrosis or pulmonary hyper-
ension and the use of cardiopulmonary bypass were asso-
iated with a significantly greater risk of death within 30
ays after lung transplantation (Table 4). Although the risk
f death within 30 days tended to be increased in recipients
f donors aged 60 years and older, it did not reach statistical
ignificance. Other factors, such as recipient age, type of
ransplant, and preservation solution, did not affect the
0-day mortality.
A total of 210 patients died after a median follow-up of
5 months (range 0-136 months). The overall 5- and 10-year
umulative survivals were 57% and 38%, respectively (Fig-
re 2). However, the 10-year survival tended to be worse in
he older donor group (16% vs 39% in the younger donor
roup, P  .07) (Figure 3). The long-term survival was not
able 4. Risk factors for 30-day mortality
otential risk factors P-value 95% CI
ransplantation performed for pulmonary
fibrosis or pulmonary hypertension
0.001 1.5-5.1
tilization of cardiopulmonary bypass 0.0003 1.7-6.1
onor age 60 years old 0.09 0.9-4.1
ecipient age (60 years old vs 60
years old)
0.5 0.4-1.6
ype of lung transplant (bilateral vs single) 0.4 0.3-1.6
reservation solution (Euro-Collins versus
Perfadex)
0.7 0.6-2.3Figure 2. Cumulative overall survival for all 467 recipients.
O
28 The Journal of Thoracic and Cardiovascular Surgery ● Febrnfluenced by recipient gender (male vs female, P  .5),
ecipient age (60 years vs  60 years, P  .3), or type of
ransplant (single vs bilateral, P  .7). The long-term sur-
ival was not significantly different between patients who
nderwent transplantation for emphysema (38% at 10
ears), cystic fibrosis (34% at 10 years), pulmonary fibrosis
38% at 10 years), or pulmonary hypertension (55% at 10
ears) (P  .4).
The causes of death were primarily bronchiolitis obliter-
ns syndrome (BOS) and sepsis among recipients who sur-
ived for more than 90 days posttransplantation (Table 5). A
otal of 56 patients died of BOS, and 54 patients died of
epsis. BOS was the predominant cause of death in recipi-
nts of the older donor group who survived for more than 90
ays after surgery, whereas sepsis was the predominant
ause of death in recipients of the younger donor group who
urvived for more than 90 days after surgery. A total of 11
atients (65%) died of BOS in the older donor group,
hereas 45 patients (34%) died of BOS in the younger
onor group (P  .01). The other causes of death were not
ignificantly different between the 2 groups.
igure 3. Cumulative overall posttransplant survival of recipients
ho received lung transplants from donors aged more than and
ess than 60 years.
able 5. Causes of death in recipients who died more than
0 days after their transplant
Older donors
(n  17)
Younger donors
(n  132) P-value
ronchiolitis obliterans
syndrome
11 45 0.01
epsis 4 50 0.3
evere acute rejection 0 2 0.6
ancer 0 10 0.2
ardiac complications 0 2 0.6
eurologic complications 1 3 0.4
ther 1 20 0.3
uary 2007
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TXA total of 10 recipients received lungs from donors aged
0 years or more (median age 73 years, range 70-77 years).
ecipient diagnoses were pulmonary fibrosis (n  4), em-
hysema (n  2), cystic fibrosis (n  2), sarcoidosis (n 
), and idiopathic pulmonary hemosiderosis (n  1). All
atients underwent bilateral lung transplantation. One pa-
ient died of primary graft dysfunction within 30 days of
urgery, 1 patient died of sepsis 6 weeks after surgery, and
 patient died of BOS 16 months after surgery. Seven
atients are alive 6 to 82 months after transplantation with
cumulative 5-year survival of 60%.
iscussion
he constantly increasing number of patients awaiting lung
ransplantation has led to a critical shortage of lung donors.
herefore, over the past few years, lung donor selection
riteria have been progressively liberalized. Donors with
rolonged intubation, significant smoking history, history of
sthma, or abnormal chest radiography have been used for
ransplantation without significant impact on the early post-
perative outcome.6,7 Although donors aged more than 55
ears represent a large group of potentially available donors,
ost programs have remained skeptical about using older
onors for lung transplantation. Some reports mentioned the
se of occasional donors aged more than 55 years, but the
umber has remained small and has generally been limited
o donors aged less than 60 years.6-8
During the last few years, we have taken the policy to
onsider all donors for lung transplantation and to avoid
isqualifying donors on the basis of age only. This study
as performed to review our experience with the first 60
onsecutive donors aged 60 years or more whom we have
sed for lung transplantation in our program. Most of the
lder donors were nonsmokers, were intubated for less than
days, and presented with normal bronchoscopy and nor-
al chest radiography. However, with increasing experi-
nce, we have become less restrictive and occasionally
ccepted older donors with a history of smoking, abnormal
hest radiography, or a PAO2 less than 300 mm Hg.
To evaluate the impact of older donors on early and late
utcome after lung transplantation, we have used for com-
arison the group of 407 consecutive recipients receiving
ungs from donors aged less than 60 years during the same
ime period at our institution. When comparing the 2
roups, we observed that the 30-day postoperative mortality
as increased when older donors were used in recipients
ho underwent transplantation for pulmonary fibrosis and
ulmonary hypertension. In contrast, only 1 patient who
nderwent transplantation for cystic fibrosis and no patient
ho underwent transplantation for emphysema died within
0 days of transplant in the older donor group. Thus, these
ndings suggest that older donors can be safely used inow-risk recipients. In high-risk recipients (eg, those with p
The Journal of Thoraciculmonary hypertension or pulmonary fibrosis), however,
he use of older donors should be carefully evaluated.
Evaluation of the operative risk should be determined by
he quality of the donor, length of ischemic time, and
ecipient risk factors.11-13 An analysis from the United
etwork for Organ Sharing database showed that the inter-
ction of older donor age and prolonged ischemic time was
ssociated with increasing mortality at 1 month and at 1
ear after lung transplantation.14 Although this study had
nly 23 donors aged more than 55 years, it is interesting to
ee that the postoperative mortality rate exponentially in-
reased in donors aged more than 55 years when the isch-
mic time was more than 7 to 8 hours. In our experience, the
otal ischemic time for the second lung was less than 8 hours
n all but 4 recipients with donors aged 60 years or more. It
ust be noted, however, that lung preservation has im-
roved over the years and that the ischemic time seems to
ave less importance because the use of Euro-Collins was
witched to Perfadex.9
The long-term outcome after lung transplantation can be
nfluenced by donor lung characteristics. Ciccone and col-
eagues15 showed that recipients of donors with traumatic
rain death experienced more severe rejection episodes dur-
ng the first year posttransplantation and were predisposed
o earlier development of BOS. In our experience, recipients
f donors aged 60 years or more had lower 5- and 10-year
urvivals than recipients of younger donors. In addition, the
ause of death was predominantly BOS in the older donor
roup, whereas it was predominantly sepsis in the younger
onor group. Lower survival at 5 years after transplantation
as also been observed in kidney and liver recipients who
eceived their organs from donors aged more than 60
ears.16,17 Thus, considering the total burden of injury that
he transplanted organ is expected to endure, not unexpect-
dly, the use of older donors is associated with lower long-
erm survival. However, given the current lack of organ
onors, lungs transplanted from donors aged 60 years or
ore can save the lives of many patients who would oth-
rwise be at risk of dying of end-stage lung disease while on
he waiting list.
The proportion of cadaveric donors aged 60 years or
ore has been progressively increasing over the past decade
nd now exceeds 10% of all cadaveric donors available for
ransplantation.18,19 In Canada, the rate of cadaveric donors
ged 60 years or more has increased from 6% in 1992 to
5% or more in 1998 and thereafter.19 Thus, liberalization
f the age as criteria for lung donation could significantly
xpand the number of organs available. In our experience,
he proportion of donors aged 60 years or more has varied
etween 15% and 20% of all lung transplantations per-
ormed since 2001 at our institution. These organs have
een mainly allocated to older recipients and the most ill
atients on the waiting list.
and Cardiovascular Surgery ● Volume 133, Number 2 529
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5
TXonclusions
his study demonstrates that lungs from older donors could
e considered for transplantation if they fulfill all other lung
onor selection criteria. An evaluation of the postoperative
isk should, however, be performed on the basis of donor
haracteristics and recipient diagnosis. Recipients with pul-
onary fibrosis or pulmonary hypertension certainly present
igher-risk recipients in whom older donors should be used
autiously. Although donor age can affect long-term sur-
ival posttransplantation, given the current shortage of or-
ans, older donors should be considered for lung transplan-
ation and not be discarded on the basis of age only.
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iscussion
r J. Wain (Boston, Massachusetts). I thank the Society for the
pportunity to discuss the article and congratulate Dr De Perrot
nd the Toronto group on an impressive experience and a timely
resentation for us about lung transplantation. The issue of a
imited supply of donors for lung transplantation is truly critical at
he present time, and the group here is certainly to be congratulated
or the courage to take donors in increasing numbers, both 60 and
0 years of age or older, as well as the forthright presentation of
he results in using these donors themselves. I think the general
onclusion of the study, that donors more than 60 years of age can
rovide acceptable organs for lung transplantation in selected
ircumstances, is sound and valid. The results of the study cer-
ainly underscore the paradigm that, short of active malignancy, no
ne single demographic or physiologic characteristic should rule
ut a potential lung donor candidate, and clearly age should be
hrown out based on this experience. I have 4 questions. First, the
ime course of the study, 1994 to 2005—did you use any older
onors before 1994? Was that the first year that you began using
hose donors?
Dr De Perrot. Yes, 1994 was the first year a donor older than
0 years was used in our experience.
Dr Wain. Great. That’s what I presumed was probably the
ase, because you can clearly see from the graph that you were
sing more and more of the donors over time.
Second, why do you think it is that the older donors don’t do as
ell in recipients with a diagnosis of pulmonary fibrosis or pul-
onary hypertension? Do you think there is intrinsic disease in
hose donor lungs that is not identified, or is there some other
actor?
Dr De Perrot. I think the older donors don’t have the same
otential to sustain postoperative complications as younger donors
o. One question that we are starting to look at is pulmonary
ypertension. We are trying to determine whether the patient with
ulmonary fibrosis who died with older lungs had high pulmonary
rtery pressures at the time of surgery or not, but I don’t have the
ata yet.
Dr Wain. Well, that would certainly make sense, and from that
erspective, are there any other studies one can do on these older
onors before procurement, such as a computed tomography scan
r angiographic imaging, that might help you to select them better?
Dr De Perrot. We haven’t done any of that. It’s always
otentially a problem to have underlying lung disease that you
on’t detect at the time of retrieval. The risk is higher in older
onors but can be encountered in younger donors too. What we
ave done in addition to our standard evaluation is more routinely
easure the pulmonary artery pressures in the donor. Certainly this
eries of donors, in addition to the age, have been very good
onors. So the older they get, the more strict we are with the
riteria other than age.
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De Perrot et al Cardiothoracic TransplantationDr Wain. I see. The last question, really to help guide the rest
f us if we’re not quite as brave as you are, is how would you
escribe the ideal recipient for a set of lungs from a donor aged
ore than 60 years, and perhaps more important, who would you
ay absolutely should never get a set of donor lungs from someone
ged more than 60 years?
Dr De Perrot. I would be very cautious about using older lungs
or patients with pulmonary hypertension, but it really comes down
o how sick the recipients are on the waiting list. These lungs have
een used for recipients who were very sick and would not have
urvived for long without a transplant.
Dr Wain. The recipient age, for instance, wouldn’t be some-
hing that you would look at critically?
Dr De Perrot. We would rather put old lungs into an old
ecipient, but if you have somebody who is young and very sick on
he waiting list, we would use these lungs as well.
Dr J. Sonett (New York, New York). So you would use a
2-year-old lung in a 20-year-old with cystic fibrosis even with the
uestionable increased BOS rate?
Dr De Perrot. Yes. If the recipient is clearly sick, for instance,
ith high CO2 or in the hospital on biphasic positive airway
ressure, we would use these lungs.
Dr Wain. I congratulate you on this study, and I want to hear
ore about it in a couple of years and see how things continue to
urn out.
Dr S. Keshavjee (Toronto, Ontario, Canada). I know Marc
entioned measuring pulmonary artery pressures, and if your
onor doesn’t have a Swan, one should at least check it with a
ressure line, because we have turned down some older donors in
hom we found significant pulmonary hypertension at the time of
rgan retrieval. Furthermore, it is important to note that when you
ook at our experience of the mortalities in those with idiopathic
ulmonary fibrosis and primary pulmonary hypertension with an
ld donor, it’s often that clinical situation in which you have a
ecipient who is desperately ill and you stick your neck out
hinking, well, this is going to be their last chance, and yes, it’s
isky, but they don’t really have another opportunity; however,
hen you look back at your data you inevitably see increased
ortality in the high-risk recipients, such as those with pulmonary
ypertension. So when Dr Wain asked the question of who abso-
utely shouldn’t get it, one needs to examine this in the context of
he fact that often when we do that, it’s in extenuating clinical
ircumstances, of compounding risks, using a high-risk donor for
high-risk recipient.
Dr Y. Toyoda (Pittsburgh, Pennsylvania). I have a similar
uestion. We performed 91 lung transplants last year. Of these,
bout 10% had donors aged 60 years or more. So we are very
The Journal of Thoracicomfortable with the donor age up to 65 years now, but beyond 65
ears, we try to use donors locally. We use older donors for older
ecipients. Is your conclusion that older donors provide a worse
utcome perhaps related to the older recipient population?
Dr De Perrot. Using older donors for older recipients can
rovide a worse outcome?
Dr Toyoda. Yes, worse survival.
Dr De Perrot. The recipient age doesn’t seem to be a factor
hat will lead to more complications. Recipients with pulmonary
brosis are usually older, but the recipient age in itself, in our
xperience at least, didn’t seem to make a difference in the
ecovery from the surgery.
Dr P. Theodore (San Francisco, California). Marc, thank you
or that lucid presentation. We have been impressed, and your data
eem similar in a lot of the ischemia-reperfusion injury that we see
n older donors, and I noticed in those patients who died, it looked
ike upward of 30% had primary graft dysfunction. I have often
ondered if the older donors are less tolerant of periods of cold
schemia and if you have any correlation at all in terms of the
eriod of ischemia and the outcomes related to older donors,
pecifically because their endothelial function may be somewhat
ifferent as to the donor’s age, and they may be more sensitive to
hose periods of ischemia.
Dr De Perrot. There are data from the International Society for
eart and Lung Transplantation that I’m sure you are aware of:
hey observed that the age of the donor and the ischemic time had
negative cumulative impact on outcome. But all these data were
ublished several years ago, and I think the quality of the lung
reservation has improved since then. The use of Perfadex and
ther improvements in the preservation technique have probably
elped to reduce the risk of prolonged ischemic times. In this series
f transplants, most of the ischemic times were somewhere be-
ween 6 and 8 hours. There were 4 patients who received older
ungs with an ischemic time longer than 8 hours, and they have
een doing well. I think the ischemic time doesn’t have so much
f an impact. I think it’s really more donor and recipient param-
ters that will affect the outcome.
Dr S. Yang (Baltimore, Maryland). If I could go back to the
rst article. In your data is there any way to answer some of these
ther questions about the older donor for the older patients? Were
ou able to see any trends?
Dr Nwakanma. We did not pay attention to that. It can be
one.
Dr Yang. It can be done.
Dr Nwakanma. Yes.
Dr Yang. That’s for next year’s talk.
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